Target intelligence / Profile preview

T cell receptor alpha variable 8-4 (TRAV8-4)

Target: TRAV8-4
Molecular classification: Receptor (specifically, a component of the alpha-beta T cell receptor heterodimer), Immunoglobulin superfamily domain (variable region), Non-catalytic tyrosine-phosphorylated receptor (NTR) family (by signaling mechanism)

Overview

T cell receptor alpha variable 8-4 (TRAV8-4) is a protein-coding gene segment encoding a variable region of the T cell receptor (TCR) alpha chain, crucial for antigen specificity. TRAV8-4 participates in the assembly of the TCR alpha chain, which dimerizes with a beta chain to form the heterodimeric TCR complex on T lymphocytes. This complex recognizes peptide antigens presented by major histocompatibility complex (MHC) molecules, initiating adaptive immune responses through a signal transduction cascade involving the CD3 complex and intracellular kinases. Diversity in TCR recognition is achieved through recombination and junctional diversity of variable (V), joining (J), and sometimes diversity (D) segments. TRAV8-4 is one of the human V alpha gene segments, and its usage can be tracked in immunological studies, repertoire profiling, and potentially in engineered immune therapies.

Other names: T cell receptor alpha variable 8-4TRAV8-4T cell receptor alpha chain V region PY14TCRAV1S2TCRAV8S4TRAV84T-cell receptor alpha chain V region PY14

Mechanism of action

Engage and activate antigen-specific T cells via engineered TCRs; Block or modulate downstream signaling (e.g., manipulation of ITAM phosphorylation, CD3 complex)

Biological functions

Antigen recognition (peptide antigen binding)MHC protein bindingSignal transduction: initiates intracellular signaling in T cells upon antigen-MHC engagementImmune response: critical for adaptive immunity, T cell activation, growth, and differentiation

Disease associations

Cancer (involved in anti-tumor immune response, TCR-based therapies)Infection (mediates antigen-specific T cell responses to pathogens)Inflammation (TCR signaling implicated in various inflammatory conditions)Other immunopathologies (autoimmunity, transplant rejection)

Safety considerations

Off-target immune activation (risk in adoptive T cell therapies)Autoimmunity (activation against self-antigens)Cytokine release syndrome (CRS), an adverse effect in TCR-modulating therapiesGraft versus host disease (if TCR engineering is used in cell therapy)

Interacting drugs

No specific drugs directly target TRAV8-4 as an isolated V region, but therapies such as engineered TCR-based biologics, checkpoint inhibitors, and adoptive T-cell transfers are functionally related to TCR recognition.

2 more in the full profile.

Biomarkers

T cell clonotype profiling (identification of V alpha family usage, including TRAV8-4, in disease states or response to therapy)TCR repertoire sequencing in oncology and infectious diseases

Beyond the preview

Go deeper on T cell receptor alpha variable 8-4 (TRAV8-4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha variable 8-4 (TRAV8-4).

Explore the full profile